Without a policy to reinvest savings in treating more patients, biosimilars may not improve access. Introduction Tumour necrosis factor inhibitors (shortened to TNFi) are a group of biologic medicines that are prescribed for rheumatic diseases such as rheumatoid arthritis. TNFi include adalimumab, etanercept, and infliximab. These drugs have been available now for a long time. […]
BMJ Blogs
Patient Summaries are intended to educate and inform those readers who may not be medically trained by outlining the key points of scientific articles written by medical professionals. Readers should be aware that professionals in the field may have different opinions. Any views expressed are solely those of the author(s) of the original article and are not endorsed or vetted by BMJ Publishing Group Limited (BMJ). Information is provided on an “as is” basis without any representations, conditions or warranties that it is accurate and up to date. The content is not intended to function as a substitute for a healthcare practitioner’s judgement and readers are advised to consult their own medical professional for all aspects of their health care. Readers agree not to use the content as the basis for their own medical treatment or for the medical treatment of others. To the fullest extent permitted by law, BMJ disclaims all liability and responsibility arising from any reliance placed on this content.
